Number of pages: 100 | Report Format: PDF | Published date: 13 October, 2022
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
The global peptic ulcer drugs market was pegged at US$ 4.27 billion in 2021 and is expected to witness a CAGR of 2.6% during the forecast period from 2022 to 2030.
Market Fundamentals
A peptic ulcer is a sore formed in the inner lining of the stomach, damaging the inner lining of the stomach, esophagus, and duodenum. This condition may be caused to the excess usage of pain-relieving medicines or the infectious bacterium called helicobacter pylori (H. pylori). This medical condition can further lead to severe problems, such as holes in the stomach, and serious damage to the stomach, the lower part of the esophagus, and the upper part of the duodenum. Thus, drugs are used to treat such a condition to avoid such serious complications.
[5654645]
Market Dynamics
The global peptic ulcer drugs market is growing at a rapid pace. It is estimated to show significant growth in the projected period. The growth of his market can be attributed to the increasing prevalence of peptic ulcers, the growing aged population, and rising advancements in the product. Furthermore, the rising R&D activities, development of a strong product pipeline, and growing adoption of triple therapy are also augmenting the market growth. Additionally, increasing government and private initiatives and funding/investments further fuels the expansion of the peptic drug market. Some challenges, such as the adverse effects of peptic ulcer drugs, and fluctuation in prices, can hinder the market expansion.
Market Ecosystem
The global peptic ulcer drugs market has been analyzed from four perspectives: Drug type, ulcer type, distribution channel, and region.
Peptic Ulcer Drug Market by Drug Type
[7867675]
The market has been segmented based on drug type into antibiotics, h2 antagonist inhibitors, proton pump inhibitors, and others (antacids, a prostaglandin analog, etc.). Antibiotics hold the largest share of the market, thus leading the segment. A peptic ulcer is found to be mainly caused due to helicobacter pylori infection, wherein antibiotics are utilized widely. H. Pylori infection requires triple therapy with two antibiotics and one proton pump inhibitor, thus raising the shares of the antibiotics segment. Additionally, proton pump inhibitors hold the second largest revenue share.
Peptic Ulcer Drug Market by Ulcer Type
Based on the ulcer type, the market has been segmented into a duodenal ulcer, esophageal ulcer, and gastric ulcer. Duodenal ulcer dominates the market with the largest shareholder, wherein most shares are obtained due to the high prevalence of duodenal ulcer. Increasing public knowledge of new treatments for it is one reason for its prevalence. The risk factors for duodenal ulcers are intensive smoking, higher consumption of alcohol, high stress, a large amount of consumption of spicy and oily food, and many more, thus, increasing the occurrence of duodenal ulcers. While gastric ulcer holds the second-largest revenue share in the global peptic ulcer drugs market due to rising incidences of gastric ulcers.
Peptic Ulcer Drug Market by Distribution Channel
According to distribution channels the global peptic ulcer drugs market is classified into hospital pharmacies, online pharmacies, and retail pharmacies. Due to large patient footfall, and easy availability of specialty care, the hospital segment holds the dominant position in the global peptic ulcer treatment market. Retail pharmacies maintain the second-largest stake in the market due to the rising incidence of various respiratory ailments and increased customer demand.
Peptic Ulcer Drug Market by Region
The global peptic ulcer drugs market has been segmented based on regions: North America, Europe, Asia Pacific, and the Rest of the World. North America leads the global peptic ulcer drugs market with the largest revenue share. It is also expected to maintain its dominance in the forecast period. This market's expansion may be ascribed to several elements, including the high frequency of peptic ulcers, the large base for the aged population, and the sophisticated healthcare infrastructure. North America's market is growing due to rapid expansion in R&D activities, technological progress, and high healthcare spending. The market is also expected to rise due to the approval of innovative products and drugs and a large base of market participants. Due to its developed healthcare infrastructure and high healthcare spending, Europe is the second-largest market participant.
A large geriatric population base, the rapidly evolving healthcare sector, and the quick adoption of innovative technologies are supporting the swift growth of the Asia Pacific market. Expanding the peptic ulcer drugs market in Asia is further fueled by expanding medical tourism and increased healthcare expenditure for improved medical facilities.
Competitive Landscape
The prominent players operating in the global peptic ulcer drugs market are:
Strategic Developments
|
Report Attribute |
Details |
|
Market size value in 2021 |
US$ 4.27 billion |
|
Revenue forecast in 2030 |
US$ 5.38 billion |
|
Growth Rate |
CAGR of 2.6% from 2022 to 2030 |
|
Base year for estimation |
2021 |
|
Forecast period |
2022-2030 |
|
Segments covered |
Drug type, ulcer type, distribution channel, and region. |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
The global peptic ulcer drugs market is expected to be US$ 5.38 billion in 2030.
The factors restraining the optimal growth of the global peptic ulcer drugs market are the adverse effect of drugs and fluctuation in drug prices.
The global peptic ulcer drugs market is expected to grow at a CAGR of 2.6% during the forecast period from 2022 to 2030.
The global peptic ulcer drugs market was estimated to be US$ 4.27 million in 2021.
The rise in the prevalence of peptic ulcers, growth in the geriatric population, advancement in technologies, and rapid growth in R&D activities are some factors driving the market growth.
*Insights on financial performance are subject to the availability of information in the public domain
Growth+Reports can now be customized as per client’s needs through GRG Health’s primary research and knowledge services capabilities
GRG Health’s unique GrowthMIX approach and robust research methodology helps us deliver unique & meaningful insights to our clients and uncover trends that won’t meet the standard approach
